2018 American Transplant Congress
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
Surgery, University of Wisconsin, Madison, WI.
Introduction: Basiliximab, alemtuzumab, and thymoglobulin are the most commonly used induction agents in the US. While many centers use depleting antibody induction therapy in patients…2018 American Transplant Congress
ABO-Incompatibility Lower Incidence of DSA-Induced Antibody-Mediated Rejection
Introduction:Donor-specific anti-HLA antibody (DSA) and Anti-ABO antibody are major barriers for successful kidney transplantation. Limited data are available about the existences of both DSA and…2018 American Transplant Congress
Successful Desensitization with Carfilzomib-Based Regimen to Facilitate Lung Transplantation: Initial Experience
1University of Pittsburgh, Pittsburgh, PA; 2Temple University, Philadelphia, PA.
Purpose:We describe the successful desensitization of highly sensitized lung transplant candidates (LTCs) using plasma exchange (PLEX),intravenous immunoglobulin G(IVIg),and carfilzomib.Methods:5-patient case series of successful desensitization of…2018 American Transplant Congress
The Impact of Donor Specific Alloantibodies on Long-Term Outcomes of Liver Re-Transplantation
Despite reports that associate donor specific antibody (DSA) with rejection after liver transplantation, grafts are still allocated according to blood group (ABO) but not human…2018 American Transplant Congress
Mid-Term Outcome of Donor Specific Antibody Positive Deceased Donor Kidney Transplantation with Peri-Transplant Desensitization
Donor specific HLA-antibodies (DSA) remain a large barrier to successful kidney transplantation and there is a limited knowledge about desensitization strategies in deceased donor programs.Anti…2018 American Transplant Congress
Targeting Plasma Cells with Anti-CD38mAb (Daratumumab) and CXCR4 Antagonist (Plerixafor) for Desensitization
1Surgery, Duke University, Durham, NC; 2Surgery, Mayo Clinic, Rochester, MN.
[Introduction] Sensitized patients comprise a significant portion (30%) of candidates on the transplant waiting list. Unfortunately for sensitized patients, the presence of donor-specific antibodies (DSA)…2018 American Transplant Congress
Kidney Allograft Vascular Disease Post-Transplant (KTX): Risk Factors and Implications
1Medicine, Mayo Clinic, Rochester, MN; 2Pathology, Mayo Clinic, Rochester, MN.
Background: Over time grafts develop arteriosclerosis (ART)and arteriolar hyalinosis (AH). Previous studies associated AH with calcineurin inhibitors (CNI), diabetes (DM), kidney age and hypertension. Other…2018 American Transplant Congress
B-Cell Depletion with Rituximab Exacerbates Anti-Donor CD4+ T-Cell Responses in Patients with Donor-Specific Anti-Human Leukocyte Antigen Antibodies
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Background: It has been reported that preformed donor-specific anti-human leukocyte antigen antibodies (DSAs) were associated with poor graft outcomes in kidney transplant recipients. To eliminate…2018 American Transplant Congress
In Vivo Administration of Plerixafor and Bortezomib Results in Bone Marrow Plasma Cell Mobilization and Death While Inducing Biphasic Plasma Cell Apoptosis in Peripheral Blood
1U Cincinnati, Cincinnati; 2Cincinnati Children's, Cincinnati; 3Duke, Durham.
Bone marrow (BM) plasma cells (PC) secreting HLA antibody (Ab) remain a persistent reservoir of donor specific Ab and present a significant hurdle to allograft…2018 American Transplant Congress
Chronic Antibody Mediated Rejection in Renal Allografts Shows RNA Transcript Patterns That Evolve with Stage
1Massachusetts General Hospital, Boston, MA; 2University of Alberta, Edmonton, AB, Canada.
Purpose. Four stages of chronic antibody mediated rejection (CAMR) in renal allografts have been defined in humans and non-human primates (NHP), beginning with donor specific…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 40
- Next Page »